Maxigen Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	649.53	576.19	639.05	431.08	790.95	513.31
Short-Term Investments	301.5	300	-	-	8.82	13.84
Cash & Short-Term Investments	951.03	876.19	639.05	431.08	799.76	527.15
Cash Growth	35.30%	37.11%	48.24%	-46.10%	51.72%	151.31%
Accounts Receivable	123.08	132.19	103.91	88.31	98.86	109.95
Other Receivables	-	-	-	8.75	1.42	4.76
Receivables	123.08	132.19	103.91	97.06	100.27	114.71
Inventory	91.37	99.19	75.76	85.32	75.41	80.63
Prepaid Expenses	14.09	11.97	9.82	4.52	15.41	47.78
Other Current Assets	0.54	1.93	1.79	1.58	2.39	13.29
Total Current Assets	1,180	1,121	830.33	619.56	993.25	783.55
Property, Plant & Equipment	447.61	442.83	430.36	424.18	434.62	465.45
Long-Term Investments	317.64	279.68	311.31	432.8	-	-
Other Intangible Assets	0.65	0.73	0.13	0.49	1.16	1.83
Long-Term Deferred Tax Assets	1.7	1.13	2.55	5.83	3.19	0.38
Other Long-Term Assets	43.13	47.31	7.81	10.13	15.5	13.97
Total Assets	1,991	1,893	1,582	1,493	1,448	1,265
Accounts Payable	80.61	88.22	49.98	17.17	35.94	40.15
Accrued Expenses	-	83.11	72.07	64.63	55.35	40.35
Short-Term Debt	100	100	-	-	-	-
Current Portion of Leases	-	-	-	-	-	2.36
Current Income Taxes Payable	40.61	29.61	25.52	24.47	27.17	9.28
Current Unearned Revenue	33.03	15.1	22.93	1.34	4.25	11.13
Other Current Liabilities	101.26	33.07	35.37	23.78	28.79	12.8
Total Current Liabilities	355.51	349.11	205.87	131.37	151.5	116.07
Long-Term Leases	-	-	-	-	-	7.28
Long-Term Deferred Tax Liabilities	0.97	1.18	0.93	0.49	0.55	-
Other Long-Term Liabilities	7.8	5.26	0.56	0.02	0.02	0.12
Total Liabilities	364.27	355.54	207.36	131.88	152.07	123.47
Common Stock	896.8	896.8	891.63	889.34	846.99	769.99
Additional Paid-In Capital	331.58	331.29	326.93	296.1	281.9	264.39
Retained Earnings	587.28	534.5	344.12	244.46	169.8	110.3
Comprehensive Income & Other	-189.11	-225	-187.56	-68.79	-3.04	-2.96
Total Common Equity	1,627	1,538	1,375	1,361	1,296	1,142
Shareholders' Equity	1,627	1,538	1,375	1,361	1,296	1,142
Total Liabilities & Equity	1,991	1,893	1,582	1,493	1,448	1,265
Total Debt	100	100	-	-	-	9.64
Net Cash (Debt)	851.03	776.19	639.05	431.08	799.76	517.51
Net Cash Growth	21.08%	21.46%	48.24%	-46.10%	54.54%	161.86%
Net Cash Per Share	9.49	8.59	7.12	4.82	8.95	6.12
Filing Date Shares Outstanding	89.68	89.68	89.16	88.93	88.93	88.93
Total Common Shares Outstanding	89.68	89.68	89.16	88.93	88.93	88.93
Working Capital	824.59	772.36	624.47	488.19	841.75	667.49
Book Value Per Share	18.14	17.15	15.42	15.30	14.57	12.84
Tangible Book Value	1,626	1,537	1,375	1,361	1,294	1,140
Tangible Book Value Per Share	18.13	17.14	15.42	15.30	14.56	12.82
Land	-	133.23	133.23	133.23	133.23	133.23
Buildings	-	-	310.48	307.74	303.11	302.48
Machinery	-	542.5	181.24	160.52	149.88	162
Construction In Progress	-	13.01	20.08	17.67	21.6	18.79
Leasehold Improvements	-	13.43	13.43	18.91	18.91	23.7

Source: S&P Global Market Intelligence. Standard template. Financial Sources.